Avivagen Inc. Announces Results for the Second Quarter Ending April 30, 202
Ottawa, ON /Business Wire/ June 6, 2023/ Avivagen Inc. (TSXV:VIV) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, has announced its unaudited financial results for the Second quarter of 2023. […]
Avivagen Announces Significant Increase in Sales to an Existing Customer
Ottawa, ON /Business Wire/ May 25, 2023 /Avivagen Inc. (TSXV.VIV) (“Avivagen” or the “Company”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, is pleased to announce that an existing customer has […]
Avivagen Announces Review of Strategic Alternatives
Ottawa, ON /Business Wire/ May 18, 2023 /Avivagen Inc. (TSXV.VIV) (“Avivagen” or the “Company”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, announces the appointment of a Special Committee of the […]
Avivagen Announces AGM Results
Ottawa, ON /Business Wire/ April 19, 2023 / Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen” or the “Company”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, today announced the results of its annual […]
Avivagen Inc. Announces Results for the First Quarter Ending January 31, 2023
Ottawa, ON /Business Wire/ March 16, 2023/ Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, has announced its unaudited financial results for the first quarter of […]
Avivagen Reports Fiscal Year 2022 Financial Results and Strategic Initiatives to Accelerate Growth
New approvals for sales in multiple countries Raised more than $8.5 million in equity and debt financing Revenues of approximately $1 million Succession plan implemented to support next phase of accelerated growth Ottawa, ON /Business Wire/ February 22, 2023 / – Avivagen Inc. (TSXV:VIV) (“Avivagen”, the “Corporation”), a life sciences corporation focused on developing and […]
Avivagen Announces Foundational Scientific and Commercial Evidence of OxC-Beta™ Product Published in Peer-Reviewed Journal
Publication showcases the cumulative understanding to-date of Avivagen’s product from both a scientific and real world application perspective Product’s value and safety has been shown through use in many settings, under differing conditions and in millions of animals Ottawa, ON /Business Wire/ January 19, 2023 /– Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences […]
Avivagen Inc. Announces Securites for Service Agreements with CEO and CSO
Ottawa, ON / Business Wire/ December 22nd 2022 – Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Company”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhance and support immune function, thereby supporting general health and performance, announces that, pursuant to Policy 4.4 of the TSX […]
Avivagen Inc. Announces Closing of Second Tranche of a Private Placement of Shares
Ottawa, ON / Business Wire/ October 31, 2022 – Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Company”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhance and support immune function, thereby supporting general health and performance, announces that it has closed the second tranche (the […]
Avivagen Inc. Announces Closing Of First Tranche Of A Non-brokered Private Placement Of Shares For Proceeds Of Up To $1.0 Million
**NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.** Ottawa, ON / Business Wire/ October 21, 2022 – Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Company”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhance and support immune […]
